Want to see COO full AI Analyst Report?
Top Page
Cooper Co
(NASDAQ:COO)
Select Model
Select Model
Rating:54Neutral
Price Target:
$63.00
▼(-13.32% Downside)
Action:Reiterated
Date:09/15/26
COO’s score is held back primarily by sharply weaker TTM cash flow and compressed operating margins, despite solid revenue growth and a conservatively levered balance sheet. Technically, the stock is in a strong downtrend (well below key moving averages) even though it is extremely oversold. Valuation is moderate at ~18.5x earnings, while the latest earnings call was supportive on execution/cash flow and capital returns but tempered by soft near-term guidance and expected Q4 margin pressure.
Positive Factors
Revenue Growth
Sustained top-line growth indicates continued demand across CooperVision and CooperSurgical rather than reliance on a single product. This expanding revenue base can support investment in innovation, broaden customer relationships, and provide operating leverage if margin execution improves over the next several quarters.
Negative Factors
Cash Conversion
The sharp deterioration in operating and free cash flow weakens earnings quality and reduces internally generated funding for research, capacity, acquisitions or shareholder returns. Unless cash conversion normalizes, working-capital or spending pressure could constrain financial flexibility despite manageable leverage.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained top-line growth indicates continued demand across CooperVision and CooperSurgical rather than reliance on a single product. This expanding revenue base can support investment in innovation, broaden customer relationships, and provide operating leverage if margin execution improves over the next several quarters.
Read all positive factors
Cooper Co Key Performance Indicators (KPIs)
Any
Revenue by Segment
Shows how different parts of the business contribute to overall sales, highlighting strengths and potential areas for growth within the company's diverse operations.
Shows how different parts of the business contribute to overall sales, highlighting strengths and potential areas for growth within the company's diverse operations.
Data provided by:
The Fly
The FlyCooper Co (COO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$11.24B
Dividend Yield0.02%
Average Volume (3M)5.05M
Price to Earnings (P/E)20.1
Beta (1Y)0.57
Revenue Growth4.73%
EPS Growth43.89%
CountryUS
Employees15,000
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)2.93
Shares Outstanding190,155,290
10 Day Avg. Volume3,440,776
30 Day Avg. Volume5,049,924
Financial Highlights & Ratios
PEG Ratio-8.14
Price to Book (P/B)1.70
Price to Sales (P/S)3.42
P/FCF Ratio32.24
Enterprise Value/Market Cap1.46
Enterprise Value/Revenue3.87
Enterprise Value/Gross Profit6.07
Enterprise Value/Ebitda17.99
Forecast
1Y Price Target
$64.83Price Target Upside-10.80% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)4.54
Revenue Forecast (FY)$4.24B
Cooper Co Business Overview & Revenue Model
Company Description
The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in cont...
Cooper Co Earnings Call Summary
Earnings Call Date:Sep 09, 2026
(Q3-2026)
| % Change Since: |
Next Earnings Date:Dec 03, 2026
Earnings Call Sentiment Positive
The call was broadly positive: the company delivered an earnings beat, record quarterly free cash flow, an 86% year-to-date free cash flow increase, a favorable tax resolution, substantial share repurchases and continued fertility and product momentum. These strengths were tempered by flat CooperVision revenue, U.S. channel destocking that will continue into Q4, legacy hydrogel declines, China and Asia Pacific challenges, near-term margin pressure and a higher expected fiscal 2027 tax rate. Management expressed confidence that inventory actions will be completed in Q4 and that increased commercial investment will support improved growth.Positive Updates
Earnings Beat Expectations
Non-GAAP EPS increased 4% year-over-year to $1.15, including approximately $0.03 from tariff refunds. This was the company's 11th consecutive quarter exceeding consensus earnings expectations.
Negative Updates
CooperVision Revenue Flat in Q3
CooperVision revenue was $717 million, essentially flat year-over-year. Results in the Americas reflected proactive U.S. channel inventory reductions.
Read all updates
Q3-2026 Updates
Positive
Negative
Earnings Beat Expectations
Non-GAAP EPS increased 4% year-over-year to $1.15, including approximately $0.03 from tariff refunds. This was the company's 11th consecutive quarter exceeding consensus earnings expectations.
Read all positive updates
Company Guidance
For Q4, the company expects consolidated revenue of $1.057 billion to $1.08 billion, representing organic growth of 0% to 2%; CooperVision revenue of $692 million to $706 million, down 2% to flat organically; CooperSurgical revenue of $364 million to $374 million, representing organic growth of 4% to 6%; interest expense of roughly $25 million; a non-GAAP effective tax rate of roughly 16%; non-GAAP EPS of $1.05 to $1.09; and around $170 million of free cash flow, excluding litigation-related payments of roughly $272 million. MiSight growth is expected to be in the low teens in Q4, resulting in roughly 20% growth for this full year, while the company expects $2.2 billion of cumulative free cash flow in fiscal '26 to 2028 and, in fiscal 2027, its scheduled GILTI increase of roughly 2% to increase the non-GAAP effective tax rate from roughly 15.5% this year to roughly 17.5% in fiscal 2027.Cooper Co Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
78
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 | Oct 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.24B | 4.09B | 3.90B | 3.59B | 3.31B | 2.92B |
| Gross Profit | 2.70B | 2.48B | 2.60B | 2.36B | 2.14B | 1.96B |
| EBITDA | 910.30M | 1.05B | 1.07B | 885.90M | 878.70M | 823.90M |
| Net Income | 570.30M | 374.90M | 392.30M | 294.20M | 385.80M | 2.94B |
Balance Sheet | ||||||
| Total Assets | 12.67B | 12.39B | 12.32B | 11.66B | 11.49B | 9.61B |
| Cash, Cash Equivalents and Short-Term Investments | 154.70M | 110.60M | 107.60M | 120.90M | 138.20M | 95.90M |
| Total Debt | 2.54B | 2.78B | 2.58B | 2.57B | 2.76B | 1.48B |
| Total Liabilities | 4.34B | 4.16B | 4.23B | 4.11B | 4.32B | 2.66B |
| Stockholders Equity | 8.33B | 8.24B | 8.08B | 7.55B | 7.17B | 6.94B |
Cash Flow | ||||||
| Free Cash Flow | 678.00M | 433.70M | 288.10M | 215.00M | 450.40M | 524.20M |
| Operating Cash Flow | 1.03B | 796.10M | 709.30M | 607.50M | 692.40M | 738.60M |
| Investing Cash Flow | -361.50M | -372.90M | -764.60M | -449.00M | -1.83B | -450.30M |
| Financing Cash Flow | -641.00M | -425.90M | 39.20M | -173.90M | 1.19B | -311.40M |
Cooper Co Technical Analysis
Neutral
72.68
Price Trends
62.23
Negative
66.23
Negative
69.58
Negative
Market Momentum
-0.34
Negative
63.26
Neutral
94.97
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COO, the sentiment is Neutral. The current price of 72.68 is above the 20-day moving average (MA) of 56.72, above the 50-day MA of 62.23, and above the 200-day MA of 69.58, indicating a neutral trend. The MACD of -0.34 indicates Negative momentum. The RSI at 63.26 is Neutral, neither overbought nor oversold. The STOCH value of 94.97 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for COO.
Cooper Co Risk Analysis
Cooper Co disclosed 41 risk factors in its most recent earnings report. Cooper Co reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cooper Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $5.44B | 37.31 | 9.07% | ― | 10.51% | 20.67% | |
58 Neutral | $5.53B | -5.60 | -31.83% | 1.04% | -14.49% | -644.98% | |
58 Neutral | $6.05B | -35.93 | -2.67% | ― | 8.85% | 37.70% | |
57 Neutral | $12.67B | -12.11 | -16.60% | 0.16% | 5.36% | -632.85% | |
56 Neutral | $1.08B | 270.13 | 1.08% | ― | 51.30% | ― | |
54 Neutral | $11.24B | 20.13 | 6.88% | 0.02% | 4.73% | 43.89% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
COO
Cooper Co
61.65
-12.87
-17.27%
BAX
Baxter International
25.65
2.70
11.79%
MMSI
Merit Medical Systems
93.94
10.61
12.73%
STAA
Staar Surgical
22.49
-4.47
-16.58%
TFX
Teleflex
136.58
5.69
4.34%
BLCO
Bausch + Lomb Corporation
17.43
1.65
10.46%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.